ZTS - Leadership updates

Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu

Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand

Animal welfare nonprofit bolsters board to better serve the needs of pet lovers nationally SAN ANTONIO, Nov. 14, 2023 /PRNewswire/ -- Petco Love welcomes new members to its board of directors, tapping a wide range of expertise to support its lifesaving mission. Petco Love is committed to shared social values and its diverse and inclusive board composition is a significant reflection of the unified values of its communities served nationwide. Since its founding more than 20 years ago, Petco Love excels as a leader and valued partner in animal welfare by creating a better world

Zoetis Inc. (NYSE:ZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023. Ms. Banque is an accomplished global senior executive with over 30 years of experience in health sciences with top tier pharmaceutical companies. Ester will be a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230709430714/en/Ester Banque joins Zoetis as Executive Vice President and President, U.S. Operations, effective July 10, 2023. Source: Zoetis "We are excited to welcome

Johnson & Johnson executive brings valuable business leadership, consumer insights and direct-to-consumer advertising experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Vanessa Broadhurst, Executive Vice President, Global Corporate Affairs at Johnson & Johnson, to its Board of Directors. Ms. Broadhurst has deep experience in consumer insights and direct-to-consumer advertising, and her appointment increases the size of the Board from 11 to 12 members. She will serve on the Board's Quality and Innovation Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005781/en/Vanessa Broadhurst,

Dr. Catherine Knupp Culminates Remarkable Career of Advancing Animal Care with Breakthrough New Products and Continuous Innovations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Robert J. Polzer, PhD, as Executive Vice President and President of Research & Development for the company, effective Jan. 1, 2022. Polzer currently serves as Senior Vice President of Global Therapeutics for Zoetis and joined the company in 2015 after spending more than 20 years in R&D leadership roles at Pfizer. Polzer will become a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck. This press release features multimedia. View the full release here: https://www.busi

Reports Revenue of $1.9 Billion, Growing 22%, and Net Income of $559 Million, or $1.17 per Diluted Share, Increasing 32% and 33%, Respectively, on a Reported Basis for First Quarter 2021 Reports Adjusted Net Income of $603 Million, or Adjusted Diluted EPS of $1.26, for First Quarter 2021 Delivers 21% Operational Growth in Revenue and 34% Operational Growth in Adjusted Net Income for First Quarter 2021 Increases Full Year 2021 Revenue Guidance to $7.500 - $7.625 Billion and Diluted EPS of $4.08 - $4.19 on a Reported Basis, or $4.42 - $4.51 on an Adjusted Basis Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2021 and increased its guidance for ful